p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 4, 1998. Oral presentations from the public will be scheduled between approximately 10 a.m. and 11:15 a.m. on February 12, 1998, and between approximately 10:15 a.m. and 10:45 a.m. on February 13, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 4, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 13, 1998, from 9:30 a.m. to 10 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). FDA staff will present to the committee trade secret and/or confidential commercial information regarding pending and future device submissions.

FDA regrets that it was unable to publish this notice 15 days prior to the February 12 and 13, 1998, Microbiology Devices Panel of the Medical Devices meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Microbiology Devices Panel of the Medical Devices were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 26, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations. [FR Doc. 98–2465 Filed 1–30–98; 8:45 am] BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services notifies Federal

agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

This Notice is now available on the internet at the following website: http://www.health.org

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, Room 13A–54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443–6014.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

- ACL Laboratory, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840 (formerly: Bayshore Clinical Laboratory)
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615–255–2400
- Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931 / 334–263–5745
- Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513–569– 2051, (formerly: Jewish Hospital of Cincinnati, Inc.)
- American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703– 802–6900
- Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733–7866 / 800–433–2750
- Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801–583– 2787 / 800–242–2787
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783, (formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305–325–5784
- Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800–445–6917 CompuChem Laboratories, Inc., 1904
- Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900 / 800–833–3984, (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800–876–3652/ 417–269–3093, (formerly: Cox Medical Centers)
- Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, P. O. Box 88– 6819, Great Lakes, IL 60088–6819, 847– 688–2045 / 847–688–4171
- Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 941–418–1700 / 800–735–5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912–244– 4468
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800–898–0180 / 206–386–2672 (formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

- DrugScan, Înc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310 ElSohly Laboratories, Inc., 5 Industrial Park
- Dr., Oxford, MS 38655, 601–236–2609 General Medical Laboratories, 36 South
- Brooks St., Madison, WI 53715, 608–267– 6267,
- Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800–725– 3784 / 915–563–3300 (formerly: Harrison & Associates Forensic Laboratories)
- Hartford Hospital Toxicology Laboratory, 80 Seymour St., Hartford, CT 06102–5037, 860–545–6023
- LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913–888–3927 / 800– 728–4064 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America, 888 Willow St., Reno, NV 89502, 702–334– 3400 (formerly: Sierra Nevada Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800–437– 4986 / 908–526–2400 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504–361–8989 / 800– 433–3823
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389–3734 / 800–331–3734
- MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38118, 901–795–1515/800–526–6339
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43614, 419– 381–5213
- Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302–655– 5227
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800–832–3244 / 612–636–7466
- Methodist Hospital Toxicology Services of Clarian Health Partners, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317–929–3587
- Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800–752–1835/309–671– 5199
- MetroLab-Legacy Laboratory Services, 235 N. Graham St., Portland, OR 97227, 503–413– 4512, 800–237–7808(x4512)
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612–725–2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805–322–4250
- Northwest Toxicology, Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 800–322– 3361/801–268–2431
- *Oregon Medical Laboratories,* P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440– 0972, 541–341–8092
- Pacific Toxicology Laboratories, 1519 Pontius Ave., Los Angeles, CA 90025, 310–312– 0056 (formerly: Centinela Hospital Airport Toxicology Laboratory)

- Pathology Associates Medical Laboratories, 11604 E. Indiana, Spokane, WA 99206, 509–926–2400/800–541–7891
- PharmChem Laboratories, Inc., 1505–A O'Brien Dr., Menlo Park, CA 94025,415– 328–6200/800–446–5177
- PharmChem Laboratories, Inc., Texas Division, 7610 Pebble Dr., Fort Worth, TX 76118, 817–595–0294 (formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913– 339–0372/800–821–3627
- Poisonlab, Inc., 7272 Clairemont Mesa Blvd., San Diego, CA 92111, 619–279–2600/800– 882–7272
- Premier Analytical Laboratories, 15201 East I–10 Freeway, Suite 125, Channelview, TX 77530, 713–457–3784/800–888–4063 (formerly: Drug Labs of Texas)
- Presbyterian Laboratory Services, 1851 East Third Street, Charlotte, NC 28204, 800– 473–6640
- Quest Diagnostics Incorporated, 4444 Giddings Road, Auburn Hills, MI 48326, 810–373–9120/800–444–0106 (formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410– 536–1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science, CORNING National Center for Forensic Science)
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800–526–0947/ 972–916–3376 (formerly: Damon Clinical Laboratories, Damon/MetPath, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220–3610, 800–574–2474/412–920– 7733 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, 2320 Schuetz Rd., St. Louis, MO 63146, 800– 288–7293/314–991–1311 (formerly: Metropolitan Reference Laboratories, Inc., CORNING Clinical Laboratories, South Central Division)
- Quest Diagnostics Incorporated, 7470 Mission Valley Rd., San Diego, CA 92108– 4406, 800–446–4728/619–686–3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, One Malcolm Ave., Teterboro, NJ 07608 201– 393–5590 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratory)
- *Quest Diagnostics Incorporated*, 1355 Mittel Blvd., Wood Dale, IL 60191, 630–595–3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratories Inc.)
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804–378–9130
- Scott & White Drug Testing Laboratory, 600 S. 31st St., Temple, TX 76504, 800–749– 3788/254–771–8379

- *S.E.D. Medical Laboratories*, 500 Walter NE, Suite 500, Albuquerque, NM 87102, 505– 727–8800 / 800–999–LABS
- SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590, (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214–637–7236 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 352–787–9006 (formerly: Doctors & Physicians Laboratory)
- SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800– 877–7484/610–631–4600 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 847–447–4379/800–447–4379 (formerly: International Toxicology Laboratories)
- SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91405, 818–989–2520/800–877–2520
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219-234-4176
- Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602–438–8507
- St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052
- St. Lawrence Hospital & Healthcare System, Toxicology Laboratory, 1210 W. Saginaw, Lansing, MI 48915, 517–377–0520
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573–882–1273
- *Toxicology Testing Service, Inc.,* 5426 N.W. 79th Ave., Miami, FL 33166, 305–593– 2260
- TOXWORX Laboratories, Inc., 6160 Variel Ave., Woodland Hills, CA 91367, 818–226– 4373/800–966–2211 (formerly: Laboratory Specialists, Inc.; Abused Drug Laboratories; MedTox Bio-Analytical, a Division of MedTox Laboratories, Inc.)
- UNILAB, 18408 Oxnard St., Tarzana, CA 91356, 800–492–0800/818–996–7300 (formerly: MetWest-BPL Toxicology Laboratory)
- Universal Toxicology Laboratories, LLC, 10210 W. Highway 80, Midland, Texas 79706, 915–561–8851/888–953–8851
- UTMB Pathology-Toxicology Laboratory, University of Texas Medical Branch, Clinical Chemistry Division, 301 University Boulevard, Room 5.158, Old John Sealy, Galveston, Texas 77555–0551, 409–772–3197

The Standards Council of Canada (SCC) Laboratory Accreditation Program for Substances of Abuse (LAPSA) has been given deemed status by the Department of Transportation. The SCC has accredited the following Canadian laboratories for the conduct of forensic urine drug testing required by Department of Transportation regulations:

Dynacare Kasper Medical Laboratories, 14940–123 Ave., Edmonton, Alberta Canada T5V 1B4, 800–661–9876/403–451– 3702

- Gamma-Dynacare Medical Laboratories, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ON, Canada N6A 1P4, 519-679-1630
- MAXXAM Analytics Inc., 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905-890-2555, (formerly: NOVAMANN (Ontario) Inc.)

Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration. [FR Doc. 98-2413 Filed 1-30-98; 8:45 am]

BILLING CODE 4160-20-U

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4263-N-64-02]

Notice of Proposed Information **Collection for Public Comment; Consolidated Planning; Comment Due** Date

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice of proposed information collection for public comments.

SUMMARY: On December 31, 1997 (62 FR 68296), HUD published a notice of proposed information collection for Consolidated Planning for Community and Development (CPD) programs, and solicited comments on the proposed information collection. The December 31, 1997 notice inadvertently omitted the comment due date. The purpose of this notice is to advise that the comment due date for the December 31, 1997 notice is March 2, 1998.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Sheila E. Jones, Department of Housing and Urban Development, 451 7th Street, SW, Room 7230, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Sal Sclafani, Acting Director, Policy Division, 202-708-0614, ex. 4364.

SUPPLEMENTARY INFORMATION: On December 31, 1997 (62 FR 68296), HUD published a notice of proposed information collection for Consolidated Planning for Community and Development (CPD) programs, and solicited comments on the proposed information collection. The December 31, 1997 notice inadvertently omitted the comment due date. The purpose of this notice is to advise that the comment due date for the December 31, 1997 notice is March 2, 1998.

Dated: January 27, 1998. Camille E. Acevedo, Assistant General Counsel for Regulations. [FR Doc. 98-2390 Filed 1-30-98; 8:45 am] BILLING CODE 4210-29-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4196-N-06]

Announcement of Awards for the Economic Development and Supportive Services Program—Fiscal Year 1997

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Announcement of funding awards.

SUMMARY: In accordance with Section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this document notifies the public of funding awards for Fiscal Year 1997 Public and Indian Housing applicants under the Economic **Development and Supportive Services** (EDSS) Program. The purpose of this document is to announce the awards to be used to further the Department's commitment to provide economic development opportunities and supportive services to assist families, the elderly and persons with disabilities that reside in Public and Indian Housing to become self-sufficient; to live independently or to prevent premature or unnecessary institutionalization.

FOR FURTHER INFORMATION CONTACT: Maria-Lana Queen, Office of Community Relations and Involvement (OCRI), U.S. Department of Housing and Urban Development, 451 Seventh Street, S.W., Washington, DC 20410; or Tracy C. Outlaw, National Office of Native American Programs (NONAP), 1999 Broadway, Suite 3390, Box 90, Denver, CO 80202; telephone numbers: OCRI (202) 708-4214; and NONAP (303) 675-1600. Hearing- or speech-impaired persons may use the Telecommunications Devises for the

Deaf (TTY) by contacting the Federal Information Relay Services on 1-800-877-TTY (1-800-877-8339) or (202) 708-9300. (With exception of the "800" number, these are not toll free numbers.)

SUPPLEMENTARY INFORMATION: The Departments of Veterans Affairs and Housing and Urban Development, and **Independent Agencies Appropriations** Act 1997 (Pub. L. 104-204, 110 Stat. 2874; approved September 26, 1996) (FY 1997 Appropriations) set aside sixty (\$60) million for the FY 1997 ED/SS program.

Five (\$5) million of the sixty (\$60) million available under the ED/SS setaside was further allocated to the Tenant Opportunities Program (TOP) for FY 1997. Of the remaining fifty-five (\$55) million available for the ED/SS program, the following was set-aside:

- —\$5 million for the Moving to Work Demonstration;
- \$250,000 to the community of St. Petersburg, Florida for a selfsufficiency program for public housing residents (as part of a package of assistance in response to the civil disturbances in St. Petersburg);
- -\$2.5 million to be used in conjunction with funding from the Department of Health and Human Services for a Resident Uplift and Economic Development Program; and
- \$5 million for service coordinators, administered by the Office of Housing.

The remaining \$42.25 was made available for the purposes of providing grants to Public Housing Agencies and Indian Housing Authorities to enable them to establish and implement programs that increase resident selfsufficiency and support continued independent living for elderly and disabled residents.

On June 6, 1997 (62 FR 31272), HUD published a Notice of Funding Availability (NOFA) that announced \$42.25 million in ED/SS funds. The NOFA was amended as follows.

-July 17, 1997 (62 FR 38318). Corrected the maximum grant amounts for **Elderly and Disabled Supportive** Services; clarified the ineligible activities and cost items; and announced a \$1,000,000 set-aside to the Seminole Tribe of Florida (which was not funded in the FY 1996 funding cycle because of a technical computation error.

Accordingly, this document announces the recipients that were reviewed and evaluated in accordance with ranking factors set forth in the NOFA published June 6, 1997, and that funding to the Seminole Tribe of Florida was made in accordance with the amendment notice published July 17, 1997.

In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989 (103 Stat. 1987, 42 U.S.C. 3545) the Department is publishing details regarding recipients of funding awards. This information is provided in Appendix A to this document. The list of recipients may also be found on the internet site